EX-10.12.2



 Exhibit 10.12.2 
 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

  

			
	CONFIDENTIAL	  	GlobeImmune, Inc.-NCI CRADA #02264

 Amendment # 2 
 Cooperative Research and Development Agreement #02264 
 “Preclinical
and Clinical Development of GlobeImmune, Inc.’s Proprietary Yeast- 
 Based Tarmogens Expressing Tumor-Associated
Antigens for Cancer 
 Immunotherapy” 
 The purpose of this amendment is to change certain terms of the above-referenced Cooperative Research and Development Agreement (CRADA). These changes are reflected below, and except for these changes and
those of Amendment #1, all other provisions of the original CRADA remain in full force and effect. 
 The Parties agree as follows: 

1. The term of the CRADA is extended for five (5) years from May 8, 2013 to May 8, 2018. 

2. Article 7.8 is deleted. 
 3. Article 10.5 is
modified to read as follows where strikeout indicates deletions and underline indicates additions: 

10.5 New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, mutual
termination, or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that IC will have the authority to retain and
expend any funds for up to one (1) year ten (10) years subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development
activities set forth in the Research Plan and for ongoing CRADA-related expenses that arise after the expiration or termination date, such as vaccine stability testing, managing or analyzing CRADA Data and CRADA Materials, continuing ongoing
clinical trials, and conducting follow-up observations of Human Subjects treated under the CRADA, such that the authority to make these expenditures will survive the CRADA. Notwithstanding the foregoing, nothing in this Section 10.5 shall be
interpreted to require Collaborator to provide additional funds to ICD for any expenses incurred after termination of this CRADA.  
 4. The
Parties acknowledge that GlobeImmune’s year 6 CRADA fund payment for [*] will be paid later than the agreed upon date of June 7, 2013. GlobeImmune will make this payment by September 30, 2013. After the payment for year 6, the payment
schedule of Appendix B will resume. 

  
 Page 1
of 2 









 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

			
	CONFIDENTIAL	  	GlobeImmune, Inc.-NCI CRADA #02264

  

 ACCEPTED AND AGREED TO: 
 For the National Cancer Institute 
  

					
	 /s/ James H. Doroshow
	  	 	  	6/5/13                
	James H. Doroshow, M.D.	  		  	Date
	Deputy Director for Clinical and Translational Research, NCI	  		  	

 For Collaborator: 
  

					
	 /s/ Timothy C. Rodell
	  	 	  	30 July 13        
	Timothy C. Rodell, M.D.	  		  	Date
	Chief Executive Officer and President	  		  	

 Reviewed Contract 
 BY     ADS  
 Date:    6/6/13 

  
 Page 2
of 2